Literature DB >> 9466424

Phospholipase C isozymes in the human brain and their changes in Alzheimer's disease.

S Shimohama1, Y Sasaki, S Fujimoto, S Kamiya, T Taniguchi, T Takenawa, J Kimura.   

Abstract

Phosphoinositide-specific phospholipase C is a key enzyme in signal transduction. We have previously demonstrated that an isozyme of phospholipase C, phospholipase C-delta1, accumulates aberrantly in the brains of patients with Alzheimer's disease. In the present study, we examined the property of phospholipase C isozymes in human brains using the methods of chromatofocusing and gel filtration chromatography, and investigated their changes in Alzheimer's disease brains. The chromatofocusing profile of human brain phospholipase C activity on a Mono P HR column demonstrated that phospholipase C-gamma1, exhibiting an isoelectric point value of 5.2, and phospholipase C-delta1, exhibiting isoelectric point values of 5.2 and 4.6, are partly overlapped in their elution. In contrast, the elution profiles of control and Alzheimer's disease brain phospholipase C on Superdex 200 pg column gel filtration chromatography indicated that phospholipase C-gamma1 and phospholipase C-delta1 can be separated with the elution position having a molecular weight of about 240,000 and 140,000, respectively, in the human brain. Using this gel filtration chromatography it was revealed that the phospholipase C-gamma1 activity was significantly decreased and the phospholipase C-delta1 activity was significantly increased in Alzheimer's disease brains compared with controls. These results suggest that the phospholipase C isozymes are differentially involved in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9466424     DOI: 10.1016/s0306-4522(97)00342-4

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  7 in total

Review 1.  Amyloid beta peptide membrane perturbation is the basis for its biological effects.

Authors:  J N Kanfer; G Sorrentino; D S Sitar
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

2.  Targeted Lipidomics of Fontal Cortex and Plasma Diacylglycerols (DAG) in Mild Cognitive Impairment and Alzheimer's Disease: Validation of DAG Accumulation Early in the Pathophysiology of Alzheimer's Disease.

Authors:  Paul L Wood; Srikanth Medicherla; Naveen Sheikh; Bradley Terry; Aaron Phillipps; Jeffrey A Kaye; Joseph F Quinn; Randall L Woltjer
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 3.  The biochemistry of Alzheimer's disease.

Authors:  G J Stege; G J Bosman
Journal:  Drugs Aging       Date:  1999-06       Impact factor: 3.923

Review 4.  Lipids and Alzheimer's Disease.

Authors:  Yu-Chia Kao; Pei-Chuan Ho; Yuan-Kun Tu; I-Ming Jou; Kuen-Jer Tsai
Journal:  Int J Mol Sci       Date:  2020-02-22       Impact factor: 5.923

5.  Untargeted lipidomics reveals progression of early Alzheimer's disease in APP/PS1 transgenic mice.

Authors:  Xueju Zhang; Weiwei Liu; Jie Zan; Chuanbin Wu; Wen Tan
Journal:  Sci Rep       Date:  2020-09-03       Impact factor: 4.379

6.  Species-Specific Regulation of TRPM2 by PI(4,5)P2 via the Membrane Interfacial Cavity.

Authors:  Daniel Barth; Andreas Lückhoff; Frank J P Kühn
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

Review 7.  PIP2: A critical regulator of vascular ion channels hiding in plain sight.

Authors:  Osama F Harraz; David Hill-Eubanks; Mark T Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-06       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.